KRAS and colorectal carcinoma: Several retrospective analyses revealed that cetuximab treatment is ineffective in patients with KRAS mutations, thereby suggesting that the KRASgenotype is a useful predictive biomarker for cetuximab or panitumumab therapy in CRC [11-13, 15].